Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dactolisib - Novartis/Adicet Bio

Next Previous
X
Search
Drug Profile

Dactolisib - Novartis/Adicet Bio

Alternative Names: BEZ-235; Dactolisib-tosylate; NVP-BEZ-235; NVP-BEZ235-ANA; NVP-BEZ235-NX; RTB-101

Latest Information Update: 29 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Adicet Bio; Brown University Medical School; Memorial Sloan-Kettering Cancer Center; Novartis
  • Class 3-ring heterocyclic compounds; Acetonitriles; Anti-infectives; Antineoplastics; Antiparkinsonians; Antivirals; Benzenesulfonates; Heart failure therapies; Imidazoles; Nitriles; Quinolines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; COVID 2019 infections; Glioblastoma; Haematological malignancies; Heart failure; Influenza virus infections; Non-small cell lung cancer; Pancreatic cancer; Parkinson's disease; Perivascular epithelioid cell tumours; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Renal cell carcinoma; Respiratory tract infections; Solid tumours; Urinary tract infections

Most Recent Events

  • 29 Jul 2024 Discontinued - Phase-I for Heart failure (Combination therapy) in USA (PO)
  • 29 Jul 2024 Discontinued - Phase-I for Parkinson's disease (Combination therapy) in USA (PO)
  • 29 Jul 2024 Discontinued - Phase-I for Urinary tract infections in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top